Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of talquetamab step-up dosing finds CRS in 80% (no impact of prior TCE; median time to onset of 1st CRS did not differ between step-up doses) but only 4% by 4th dose (all grade 1), so maybe can be given as outpatient.”
Title: Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses
Authors: Issam S. Hamadeh, Lisa Modelevsky, Amelia Chan, Aaron Mitchell, Ross S. Firestone, Alice X. Wang, Tala Shekarkhand, Neha Korde, Malin L. Hultcrantz, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Kylee Maclachlan, Sridevi Rajeeve, Hamza Hashmi, Dhwani Patel, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio Giralt, Saad Z. Usmani, and Carlyn R. Tan
You can read the Full Article in JCO Oncology Practice.
You can find more posts featuring Robert Orlowski on OncoDaily.
